Back to Agenda
Digital Trials, Sensors, Bots, AI/Machine Learning, RWD– Will Product Approvals Be Accelerated By These New Technologies?
Session Chair(s)
Isabelle de Zegher, DrMed, MD, MS, MSc
Founder
b!loba, Belgium
Digital trials or “smart” trials, AI, Bots are the new buzzwords in our industry. But what do we mean by digital trials and how will these new technologies accelerate product approvals? Drug development timelines and cost keep increasing while reimbursement is diminishing; a paradigm shift is needed in the way we develop drugs. Will this come from new technologies and digitisation? And how will these technologies impact drug development process? What are the implications for regulators and how will they approve usage of sensors, bots and ML algorithm. Do pharma and regulators need to adapt their process and organisations (e.g., introduce a Chief Digital Officer role). And finally, will the patients accept these new technologies with increasing patient adherence and preparing a natural continuum with mHealth?
Speaker(s)
Panel Discussion
Ulo Palm, MD, PhD, MBA
Vaxxinity, United States
Chief Medical Officer
Panel Discussion
Thomas Senderovitz, DrMed, MD
NovoNordisk, Denmark
Senior Vice President, Data Science
Panel Discussion
Peter Shone
PAREXEL Informatics, United Kingdom
Corporate Vice President, R&D Engineering
Panel Discussion
Meni Styliadou
Takeda, Belgium
VP Government Affairs & Public Policy, Europe & Canada
Have an account?